Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HC-7366 |
Synonyms | |
Therapy Description |
HC-7366 is a modulator of GCN2 kinase, which potentially inhibits tumors growth (J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS3179). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HC-7366 | HC 7366|HC7366|HC 7366-K|HC7366-K|HC-7366-K | HC-7366 is a modulator of GCN2 kinase, which potentially inhibits tumors growth (J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS3179). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05121948 | Phase I | HC-7366 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | Terminated | USA | 0 |
NCT06234605 | Phase I | HC-7366 Belzutifan + HC-7366 | A Study of HC-7366 in Combination With Belzutifan (WELIRE) in Patients With Renal Cell Carcinoma | Recruiting | USA | 0 |